Predictors of stimulant abuse treatment outcomes in severely mentally ill outpatients
- PMID: 23273776
- PMCID: PMC3616149
- DOI: 10.1016/j.drugalcdep.2012.11.017
Predictors of stimulant abuse treatment outcomes in severely mentally ill outpatients
Abstract
Background: Severe mental illness is often exclusionary criteria for studies examining factors that influence addiction treatment outcome. Therefore, little is known about predictors of treatment response of individuals receiving psychosocial treatments for addictions who suffer from co-occurring severe mental illness.
Methods: The impact of demographic, substance abuse severity, psychiatric severity, and service utilization variables on in-treatment performance (i.e., longest duration of abstinence) in a 12-week contingency management (CM) intervention for stimulant abuse in 96 severely mentally ill adults was investigated. A 4-step linear regression was used to identify independent predictors of in-treatment abstinence.
Results: This model accounted for 37.4% of variance in the longest duration of abstinence outcome. Lower levels of stimulant use (i.e., stimulant-negative urine test) and psychiatric severity (i.e., lower levels of psychiatric distress), as well as higher rates of outpatient treatment utilization at study entry were independently associated with longer duration of drug abstinence.
Conclusion: These data suggest that individuals with low levels of stimulant use and psychiatric severity, as well as those actively engaged in services are most likely to succeed in a typical CM intervention. For others, modifications to CM interventions, such as increasing the value of reinforcement or adding CM to evidence based psychiatric interventions may improve treatment outcomes.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.
Conflict of interest statement
Mr. Angelo and Ms. Lowe: no disclosures to report.
Dr. McDonell is currently a Principal Investigator on a National Institute on Alcohol Abuse and Alcoholism (R01AA02024801A1; PI McDonell) grant as well as a Department of Defense grant. No other disclosures.
Drs. Lewin, Srebnik, and Short have no disclosures to report.
Dr. Roll is currently funded or has been funded in the last three years by the National Institutes of Health, the Department of Justice, Washington State, as well as funding for research months from Bristol-Myers Squibb.
Dr. Ries received funding to conduct the current study from the National Institute on Drug Abuse (5R01DA022476-07; PI Ries). : Dr. Ries has been on the speaker bureaus of Lilly, Bristol-Myers Squibb, Pfizer, Janssen, Astra-Zeneca, and Suboxone in the past five years.
References
-
- Abram KM, Teplin LA. Co-occurring disorders among mentally ill jail detainees. Am. Psychol. 1991;46:1036–1045. - PubMed
-
- Baker A, Bucci S, Lewin TJ, Kay-Lambkin F, Constable PM, Carr VJ. Cognitive-behavioral threapy for substance use disorders in people with psychotic disorders: randommised controlled trial. Br. J. Psychiatry. 2006;188:439–448. - PubMed
-
- Bartels SJ, Teague GB, Drake RE, Clark RE, Bush PW, Noordsy DL. Substance abuse in schizophrenia: service utilization and costs. J. Nerv. Ment. Dis. 1993;181:227–232. - PubMed
-
- Bellack AS, Bennett ME, Gearon JS, Brown CH, Yang Y. A randomized clinical trial of a new behavioral treatment for drug abuse in people with severe and persistent mental illness. Arch. Gen. Psychiatry. 2006;63:426–432. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical